Advertisement
The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter
Professionals >> Visit The Body PROThe Body en Espanol
Home Page for TheBody.com, the Complete HIV/AIDS Resource What's New About HIV Ask the Experts About HIV HIV/AIDS Blogs Connect With Others About HIV Just Diagnosed With HIV HIV Treatment HIV Prevention Living With HIV Personal Stories of People With HIV
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Prevention/Epidemiology

Joint Venture to Manufacture and Distribute Tenofovir Gel in Africa

From Henry J. Kaiser Family Foundation

June 16, 2011

CONRAD and the South African Government's Technology Innovation Agency (TIA) on Tuesday announced a license agreement that grants TIA the rights to manufacture and distribute tenofovir gel in Africa, according to a CONRAD statement. TIA also will establish a joint venture with drug maker Cipla Medpro and iThemba Pharmaceuticals for the registration, manufacturing and distribution of the gel in South Africa and other African nations (6/14). A large trial of tenofovir gel among women was also announced on Tuesday (6/15).

Back to other news for June 2011


This information was reprinted from kff.org with permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives, and sign up for email delivery. © Henry J. Kaiser Family Foundation. All rights reserved.


  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
 
See Also
Two New Studies Support Use of PrEP for HIV Prevention Among Heterosexual Men and Women
CDC Statement: CDC Trial and Another Major Study Find PrEP Can Reduce Risk of HIV Infection Among Heterosexuals
U. Washington Statement: Pivotal Study Finds That HIV Medications Are Highly Effective as Prophylaxis Against HIV Infection in Men and Women in Africa
iPrEx Statement: Two Major Studies Prove HIV Pre-Exposure Prophylaxis (PrEP) Works in in Heterosexual Women and Men; Build on iPrEx Data Showing PrEP Reduces HIV Infections in Men Who Have Sex With Men
More News and Research on HIV Medications for HIV Prevention
No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

 

Advertisement